Innovation1 Biotech Inc.
IVBT
$0.0002
-$0.0006-75.00%
OTC PK
| 11/30/2023 | 08/31/2023 | 05/31/2023 | 02/28/2023 | 11/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -12.82% | -12.82% | -12.82% |
| Gross Profit | -- | -- | 12.82% | 12.82% | 12.82% |
| SG&A Expenses | -71.20% | -49.99% | -20.39% | 52.26% | 406.58% |
| Depreciation & Amortization | -99.95% | -99.95% | -57.15% | 88.61% | 318,425.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -85.65% | -75.94% | -31.80% | 75.15% | 884.09% |
| Operating Income | 85.65% | 75.94% | 31.80% | -75.15% | -884.09% |
| Income Before Tax | 86.40% | 85.35% | -946.55% | -2,984.87% | -4,078.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 86.40% | 85.35% | -946.55% | -2,984.87% | -4,078.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 86.40% | 85.35% | -946.55% | -2,984.87% | -4,078.19% |
| EBIT | 85.65% | 75.94% | 31.80% | -75.15% | -884.09% |
| EBITDA | 77.61% | 61.33% | 26.42% | -30.18% | -531.59% |
| EPS Basic | 74.66% | 74.24% | -345.29% | -181.90% | -139.95% |
| Normalized Basic EPS | 64.00% | 61.85% | 78.83% | -106.20% | -104.48% |
| EPS Diluted | 74.66% | 74.24% | -345.29% | -181.90% | -139.95% |
| Normalized Diluted EPS | 64.00% | 61.85% | 78.83% | -106.20% | -104.48% |
| Average Basic Shares Outstanding | 8.84% | 32.73% | 64.80% | 189.18% | 1,113.91% |
| Average Diluted Shares Outstanding | 8.84% | 32.73% | 64.80% | 189.18% | 1,113.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |